Podocytes, the glomerular epithelial cells of the kidney, share important features with neuronal cells. In addition to phenotypical and functional similarities, a number of gene products have been found to be expressed exclusively or predominantly by both cell types. With the hypothesis of a common transcriptome shared by podocytes and neurons, digital differential display was used to identify novel podocyte-expressed gene products. Comparison of brain and kidney cDNA libraries with those of other organs identified Sam68-like mammalian protein 2 (SLM-2), a member of the STAR family of RNA processing proteins, as expressed by podocytes. SLM-2 expression was found to be restricted in the kidney to podocytes. In proteinuric diseases, SLM-2, a known regulator of neuronal mRNA splice site selection, was found significantly upregulated on mRNA and protein levels. Knockdown of SLM-2 by short interfering RNA in podocytes was performed to evaluate its biologic role. RNA splicing of vascular endothelial growth factor (VEGF), a key regulator of the filtration barrier and expressed as functionally distinct splice isoforms, was evaluated. VEGF 165 expression was found to be reduced by 25% after SLM-2 knockdown. In vivo, the glomerular expression of SLM-2 correlated with the mRNA levels of VEGF 165 . This study demonstrates the power of digital differential display to predict cell type-specific gene expression by hypothesis-driven analysis of tissue cDNA libraries. SLM-2-dependent VEGF splicing indicates the importance of mRNA splice site selection for glomerular filtration barrier function.
P odocytes represent a highly specialized cell type with complex cell function. As the final barrier of the glomerular filtration unit, podocytes build a highly complex network by interdigitating so-called foot processes (1) . Recently, several studies led to the detection of specific gene products that are crucial for the physiology of this cell type. These proteins are especially involved in the organization of the slit diaphragm (the cell-cell contact between the foot processes), the specialized cytoskeleton of podocytes, and cell adhesion to the glomerular basement membrane. Many of these proteins are reported to be expressed primarily or exclusively in neurons and podocytes. Besides nephrin, an essential protein of the slit diaphragm, densin; synaptopodin; glomerular epithelial protein 1; the synaptic vesicle molecule rab3A and its effector rabphilin-3a; and the amino acid transporters CAT3 and EAAT3 show preferential or restricted expression in both of these cell types (2) (3) (4) (5) (6) (7) (8) . This may reflect physiologic similarities, as both cells share important characteristics such as arborized cell process formation, highly specialized cell-cell contacts, and a complex cytoskeletal organization (9) .
These intriguing similarities of glomerular epithelial and neuronal cells prompted us to take advantage of the hypothesis of a shared transcriptome to predict new podocyte-expressed genes. The digital differential display (DDD) method was used to compare cDNA libraries of brain and kidney with those of all other tissues. This technique, part of the Cancer Genome Anatomy Project and available at the National Center for Biotechnology Information, exploits the large number of publicly available cDNA libraries corresponding to different tissues (10) . It permits selection of (1) cDNA libraries to be compared, (2) comparison of the constituent sequences, and (3) output of a list of differentially expressed sequences. DDD experiments have been performed successfully to compare cancerous and healthy tissue (e.g., reference 11) and to isolate cDNA specific for a given library (12) . This technique has not previously been used to predict cell type-specific gene expression by a hypothesisdriven comparison of two organs with other tissues. We searched for mRNA with high expression in brain and kidney but no or significantly lower expression in other tissues. This should allow the detection of mRNA templates preferentially expressed by renal cells with a gene expression resembling the one of brain cells. According to the shared transcriptome of podocytes and neurons, the encoded proteins should be found preferentially expressed in podocytes.
This approach allowed the prediction of Sam68-like mammalian protein 2 (SLM-2) to be expressed in podocytes, which was confirmed in vitro and in vivo. SLM-2 (13) is the gene product of the human gene KHDRBS3 on chromosome 8. The gene name is an acronym for the known characteristics of SLM-2: KH domain containing, RNA binding, signal transduction associated. Here, we demonstrate that SLM-2 is regulated in glomerular diseases and is involved in alternative mRNA splicing of the vascular endothelial growth factor (VEGF-A).
Materials and Methods

DDD
DDD, a bioinformatic tool available at the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/UniGene/info_ddd. html), analyzes the frequencies of cDNA and expressed sequence tag (EST) in expression libraries. Briefly, this technique compares the constituent sequences of different libraries to determine the relative frequency of each transcript in the libraries analyzed. Fisher exact test is used to determine the statistical significance of the number of times that sequences from the selected libraries are assigned to a specific UniGene cluster. In this manner, the relative abundance of transcripts in each of the libraries can be determined and thus differential expression of genes identified. A recently developed program, Digital Extractor (14) , was used to compare human cDNA libraries of normal adult kidney and brain with other organ cDNA libraries.
Cell Culture
Three glomerular visceral epithelial cell lines were used and cultured according to previously published protocols: A conditionally immortalized human podocyte cell line (15), a stable T-SV40 immortalized human glomerular visceral epithelial cell line (16) , and a conditionally immortalized murine podocyte cell line (17) .
Reverse Transcriptase-PCR and Real-Time Reverse Transcriptase-PCR
Total RNA was isolated using silica-gel columns following the respective protocol (RNeasy Mini; Qiagen, Hilden, Germany). Control mRNA from whole human kidney and microdissected human glomeruli were isolated according to a reported protocol (18) . Reverse transcriptase-PCR (RT-PCR) was performed using heat-activated TaqDNA polymerase (Amplitaq Gold; Applied Biosystems, Darmstadt, Germany). The amplified cDNA was analyzed on a nondenaturing 5% polyacrylamide gel, stained with Vistra Green (Amersham, Braunschweig, Germany), and visualized with ImageQuant Software on a Storm Fluorophosphorimager (both Molecular Dynamics, Krefeld, Germany). Real-time RT-PCR was performed on an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) as described previously (18) . All renal biopsies were performed according to the local ethical committees' directives, and samples were processed according to the protocol of the European Renal cDNA bank (18) .
The following oligonucleotide primers (300 nmol/L) and probes (100 nmol/L) were used: Human SLM-2 (NM 006558), sense primer 5Ј-CCG TAA AAC AGT TCC CTA AGT TCA AC-3Ј (exon 2/3, i.e., spanning exons 2 to 3), antisense primer 5Ј-CTT CCT TGG CCT TGT CTC TCA T-3Ј (exon 3/4); fluorescence labeled probe (FAM) 5Ј-CCA CGT GGC AAT TCT CTG AAG CGT TTA-3Ј; human Ankyrin repeat domain 7 (ANKRD7; NM 019644), sense primer 5Ј-CTG CAT AGA TAC CCA CAA TTC ACT G-3Ј (exon 5/6), antisense primer 5Ј-TTG TAG AAA TGG GTT CCA TAT CTT CC-3Ј (exon 6/7); and human hypothetical protein XP_172449 (XM172449), sense primer 5Ј-ACT CGC AGG CCC TGT GG-3Ј, antisense primer 5Ј-CTC GGT GTC AAG GAG CAA GAG-3Ј. Commercially available predeveloped TaqMan reagents were used for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 18S rRNA (Applied Biosystems). The primers spanning at least one exon-intron boundary did not show any amplification signal tested on genomic DNA. All primers and probes were obtained from Applied Biosystems.
Western Blot
Cultured glomerular epithelial cells were harvested with lysis buffer (50 mM Tris-HCl [pH 7.4], 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM Na 3 VO 4 , and Complete Protease Inhibitor Cocktail [Roche, Mannheim, Germany]). Extracted proteins were boiled in loading buffer for 10 min, resolved by 10% SDS-PAGE under reducing conditions, and transferred to an Immobilon-P membrane (Millipore, Eschborn, Germany). The membrane was blocked with 5% skim milk, incubated in a 1:100 dilution of a purified polyclonal goat anti-SLM-2 antibody (M20; Santa Cruz Biotechnology, Heidelberg, Germany) overnight, and rinsed with PBS that contained 0.1% Tween 20. Immune complexes were visualized using enhanced chemoluminescence (ECL; Amersham Biosciences, Freiburg, Germany). Commercially available murine brain protein extract served as positive control for SLM-2 detection (ImmunoGlobe, Himmelstadt, Germany).
Immunofluorescence
Glomerular epithelial cells were grown on collagen-coated glass coverslips for 24 h, fixed with formaldehyde (2% formaldehyde and 4% sucrose in PBS) for 5 min, incubated for 10 min with 0.3% Triton in PBS, and washed in PBS. After 30 min of incubation with blocking solution (2% FCS, 2% BSA, and 0.2% fish gelatin in PBS), the fixed cells were incubated with 1:10 to 1:50 polyclonal goat anti-SLM-2 antibody (Santa Cruz Biotechnology) for 60 min. After washing, the cells were incubated with 1:200 Cy2-labeled anti-goat antibody (Dianova, Hamburg, Germany) for 60 min. Coverslips were fixed with mowiol solution (Calbiochem-Novabiochem, Bad Soden, Germany), and fluorescence microscopy was performed.
Immunohistochemistry
Brain and kidney specimens from 3-mo-old Balb/C mice or human biopsies were fixed in 4% buffered paraformaldehyde and embedded in paraffin. Immunohistochemistry was performed on 8-m-thick brain sections and 5-m-thick kidney sections that were sequentially deparaffinized, rehydrated, and microwave-treated in 0.01 M citrate buffer. After washing, sections were incubated with 0.5% avidin and 0.01% biotin to suppress endogenous avidin-binding activity, then postfixed in a methanol-H 2 O 2 solution to block endogenous peroxidase. The specimens then were incubated sequentially with a blocking solution (Zymed, Milan, Italy), the primary polyclonal goat anti-mouse SLM-2 antibody (Santa Cruz Biotechnology), followed by the secondary rabbit anti-goat biotinylated antibody (Zymed) and the peroxidase-labeled streptavidin (Zymed). Peroxidase activity was detected with 3,5-diami-nobenzidine (Sigma, St. Louis, MO). Sections then were counterstained by Cresyl Blue (DDK, Milan, Italy), dehydrated, and mounted in Permount (DDK). Nuclear staining in the brain was taken as positive control. Specificity of antibody labeling was demonstrated by the lack of staining after substituting PBS and proper control immunoglobulins (Zymed) for the primary antibody. Positive and negative controls were run together.
Short Interfering RNA Experiments and VEGF Isoform Analysis
The conditionally immortalized human podocyte cell line (15) was transiently transfected under nonpermissive culture conditions after differentiation with sequence-specific short interfering RNA (siRNA; 200 nM) using Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany). Target sequences were KHDRBS3-2 (SLM-2 siRNA2) sense 5Ј-GGC AAG GAU GAA GAA AAG Utt-3Ј, antisense 5Ј-ACU UUU CUU CAU CCU UGC Ctt-3Ј; and KHDRBS3-3 (SLM-2 siRNA3) sense 5Ј-GGA UGA AGA AAA GUA CAU C-3Ј, antisense 5Ј-GAU GUA CUU UUC UUC AUC C-3Ј, corresponding to regions in the exon 2 of SLM-2. All siRNA, including negative control of nonspecific nucleotide sequence (negative control siRNA 1), were obtained from Ambion (Silencer siRNA; Ambion, Austin, TX).
Primers for analysis of VEGF isoforms (NM 003376) were as follows: For RT-PCR separated by gel electrophoresis, sense 5Ј-CAA ATG TGA ATG CAG ACC AAA-3Ј (exon 4/5), antisense 5Ј-GGG AGG CTC CTT CCT CCT-3Ј (3Ј-UTR), expected product size 92 bp (VEGF 121 ) and 224 bp (VEGF 165 ), respectively. The primers were designed specifically for the detection of stimulatory VEGF isoforms; recently described inhibitory VEGF isoforms were not amplified (19) . Real-time RT-PCR VEGF 165 -specific assay: Sense primer 5Ј-CAA ATG TGA ATG CAG ACC AAA GA-3Ј (exon 4/5), antisense primer 5Ј-CAG GAA CAT TTA CAC GTC TGC G-3Ј (exon 7), and fluorescence-labeled probe (FAM) 5Ј-AGC AAG ACA AGA AAA TCC CTG TGG GCC-3Ј (exon 5/7). Assay for all human VEGF-A splice isoforms: Sense 5Ј-GCC TTG CTG CTC TAC CTC CAC-3Ј (exon 1), antisense 5Ј-ATG ATT CTG CCC TCC TCC TTC T-3Ј (exon 2), internal fluorescence-labeled probe (FAM) 5Ј-AAG TGG TCC CAG GCT GCA CCC AT-3Ј (exon 1/2).
Statistical Analyses
Data are given as mean Ϯ SD. Statistical analysis was performed using Kruskall-Wallis, Mann-Whitney tests, and Pearson correlations (SPSS 12.0, SPSS Inc., Chicago, IL). P Ͻ 0.05 was considered to indicate statistically significant differences.
Results
DDD Predicts Brain/Kidney-Specific Templates
A DDD experiment was conducted to compare normal adult kidney and brain cDNA libraries (total of 63,268 sequences) with all other available normal adult tissue libraries except for testis (204,515 sequences; Figure 1 ). Testis libraries were excluded because of the significant similarity of its transcriptome to the one of brain (20) . DDD takes advantage of the UniGene database by comparing the number of times that sequences from different libraries are assigned to a particular UniGene cluster. This analysis produced 55 UniGene clusters that were specific to the brain and/or kidney pool. Two further DDD experiments were performed to isolate brain-specific and kidney-specific clusters. The subtraction of these brain-specific and kidney-specific clusters from the brain and/or kidney results identified 11 putative brain-and kidney-specific clusters. Detailed analysis of the chromosomal regions was performed. Thereby, four clusters had to be eliminated as they mapped to gene loci of previously deleted templates. From the remaining seven clusters, an automated literature search led to removal of an additional four sequences because of their known significant expression in other tissue than brain and kidney. The remaining three sequences, Ankyrin repeat domain 7 (ANKRD7), hypothetical protein XP_172449, and SLM-2 (KHDRBS3), were assumed to be potentially restricted to brain and kidney.
SLM-2 Shows a Restricted Expression in Podocytes
RT-PCR experiments were carried out with specific primers on cDNA from two human glomerular epithelial cell lines. No ANKRD7 or hypothetical protein XP_172449 mRNA templates could be amplified. RT-PCR for SLM-2 was positive in both glomerular epithelial cell lines and could also be detected on isolated human glomeruli and whole human kidney cDNA (Figure 2A) .
The protein expression of SLM-2 in glomerular epithelial cell lines was first demonstrated by Western blot. A single band of the expected size was found in two human and one murine podocyte cell line with an anti-SLM-2 antiserum; murine brain protein extract served as positive control ( Figure 2B ). Immunofluorescence experiments were performed to demonstrate the intracellular localization of SLM-2 in human podocytes. In both cell lines, a predominantly nuclear signal was evident as reported in previous studies for SLM-2 (21) ( Figure 2C) .
Furthermore, expression of SLM-2 in vivo was studied by immunohistochemistry. First, murine and human brain sections were studied to establish the antiserum for SLM-2. A nuclear signal could be demonstrated in both species as reported previously for SLM-2 (22) ( Figure 3A) . In murine kidney sections, the nuclear staining was restricted to glomerular epithelial cells ( Figure 3B) . No other glomerular cells were positive for SLM-2. Only in a few individual tubular epithelial cells Figure 1 . Schematic view of the digital differential display (DDD) experiment. Normal adult kidney and brain cDNA libraries (total of 63,268 sequences) were compared with all other available normal adult tissue libraries (204,515 sequences, testis excluded). Fifty-five UniGene clusters that were potentially specific for brain and/or kidney were retrieved. Further DDD experiments resulted in 11 clusters that were putatively specific for brain and kidney. Chromosomal localization and automated literature search led to removal of eight sequences. The expression of the remaining three sequences was predicted to be restricted to brain and kidney and therefore potentially specific for podocytes in the kidney.
could discrete nuclear signals also be detected. In human renal sections, the staining was less intense but again restricted to glomerular epithelial cells ( Figure 4B ). Summarized, these findings confirm the podocyte-specific expression of SLM-2 predicted by the computational approach.
SLM-2 Is Induced in Human Proteinuric Diseases
To study a potential regulation of SLM-2 in podocytes in vivo, we investigated the expression of SLM-2 mRNA in microdissected glomeruli from patients with proteinuria and nonproteinuric control subjects. Glomeruli from 77 patients with proteinuria and nonproteinuric control subjects were investigated Figure 4A ).
To confirm a corresponding induction on protein level, we performed SLM-2 staining of fixed sections from routine renal biopsies. In control tissue (n ϭ 5), only a minority of glomeruli showed positive nuclear staining. In contrast, sections from two different proteinuric diseases (MGN, n ϭ 5; FSGS, n ϭ 5) showed a significantly increased number of SLM-2-positive nuclei in glomerular epithelial cells (control 0.2 Ϯ 0.45, MGN 2.0 Ϯ 0.7, FSGS 2.6 Ϯ 1.14; P Ͻ 0.01 for both disease groups versus control subjects; Figure 4 , B and C).
Knockdown of SLM-2 in Podocytes Leads to Alternative Splicing of VEGF
These data may reflect a role of SLM-2 in the biology of podocytes during proteinuria. To study the role of SLM-2 in Figure 5A ). SLM-2 has been shown to influence alternative splice site selection of different genes. Two of these genes are CD44 and tau; SLM-2 promotes inclusion of the variable exon v5 in CD44 and exons 2 and 3 in tau (22) (23) (24) . Although mRNA templates for CD44 and tau could be detected in cultured human podocytes and microdissected glomeruli, only SLM-2-independent isoforms were expressed in vitro and in vivo (CD44-v5 Ϫ and tau-2 Ϫ 3 Ϫ ; data not shown). Next, VEGF-A, which is known to be expressed as alternatively spliced isoforms in podocytes, was studied and endogenous VEGF was found to be alternatively spliced after knockdown of SLM-2. SLM-2 knockdown led to a 25% reduction of the isoform VEGF 165 , which contains exon 7, compared with control conditions (VEGF 165 /all VEGF isoforms: time control set as 1.0, negative control siRNA 0.96 Ϯ 0.08, SLM-2 siRNA2 0.74 Ϯ 0.22, SLM-2 siRNA3 0.76 Ϯ 0.16; n ϭ 4; P Ͻ 0.05 for both SLM-2 siRNA; Figure 5 , B and C). This substantiates a role of SLM-2 for the inclusion of VEGF exon 7 and therefore promoting expression of VEGF 165 over VEGF 121 . As Stoss et al. (22) were able to characterize the potential binding element of SLM-2 in exonic splicing enhancers of different genes, we searched for homologies in the exon 7 of human VEGF. As shown in Figure 5D , a corresponding purin-rich binding site can also be found in exon 7 of the human VEGF gene. Nephrin, another podocyte-expressed gene with reported splice isoforms, did not show a potential SLM-2 binding element (25, 26) . As SLM-2 is significantly upregulated in proteinuric diseases, the expression of VEGF 165 was analyzed in the 77 human renal biopsies specified above. The expression of SLM-2 showed a highly significant correlation with the expression of VEGF 165 (r ϭ 0.63, P Ͻ 0.01; Figure 6 ), potentially indicating a role of SLM-2 in mRNA splice site selection in podocytes in vivo.
Discussion
The computational approach of DDD allowed the prediction of a novel podocyte expressed gene, SLM-2. Its expression is limited to glomerular epithelial cells in the kidney, it is upregulated in proteinuric diseases, and it is involved in mRNA splice site selection. SLM-2 represents a mammalian member of the STAR family; STAR is an acronym for signal transduction and activation of RNA. Its members share an extended hnRNP K homology (KH) RNA binding domain and are involved in mitosis and cell-cycle regulation, signal transduction, and alternative splice site selection (reviewed in reference 27). The best characterized member of these RNA-binding proteins is Sam68 (Src-associated substrate during mitosis of 68 kD), first described as a target of the tyrosin kinase Src during mitosis (28, 29) . SLM-2 that is closely related to Sam68 was first described by three independent groups in 1999. Di Fruscio et al. (13) detected SLM-2 by screening a ZAP II mouse brain cDNA library and demonstrated its RNA-binding potential. This RNA binding is inhibited after phosphorylation by the epithelialspecific tyrosine kinase BRK/sik (30) , whereas other kinases, such as Src and Fyn, do not phosphorylate SLM-2 (13,31). Venables et al. first showed SLM-2's nuclear localization (21); later, this group could demonstrate its regulation by proteasomic degradation (32) . A significant expression of SLM-2 in the kidney was first detected by Lee's group (33) , who was also showing that expression of SLM-2 can lead to cell growth arrest.
As presented in our study, SLM-2 is expressed in glomerular epithelial cells and influences the splice site selection of an important glomerular signal transductor, VEGF. The role of VEGF in development and function of the renal glomerulus has been studied comprehensively and was reviewed recently (34) . It appears in three major isoforms, named for the number of amino acids VEGF 121 , VEGF 165 , and VEGF 189 , corresponding on mRNA levels to exons 1 to 5 and 8 in all isoforms and additionally exon 7 (VEGF 165 ) or 6 and 7 (VEGF 189 ) (35) . In the glomerulus, all major VEGF isoforms are produced by the podocyte (36) . The VEGF receptors are found mainly on endothelial cells, but a weaker expression on podocytes suggests an additional paracrine signaling pattern. Individual VEGF isoforms play specific roles in glomerular function. Podocytespecific deletion of VEGF in mice leads to death at birth and absence of a glomerular filtration barrier (37) . Mice that express only VEGF 122 have a significant reduction in the number of vascularized glomeruli compared with controls (38) . Thus, VEGF 122 provides partial but incomplete rescue compared with the complete podocyte-specific knockout. In contrast, podocyte-specific overexpression of VEGF 165 leads to a striking collapsing glomerulopathy (37) . The systemic administration of VEGF 165 can accelerate glomerular repair in necrotizing glomerulonephritis (39) . Differences between VEGF isoforms are potentially due to differences in binding to and release from the glomerular basement membrane (40, 41) . However, little is known about the molecular regulation of alternative splice site selection of VEGF mRNA. The data presented in this study suggest a significant role of SLM-2 on isoform-specific expression of VEGF, hereby potentially influencing the functional regulation of the glomerular filter. It also demonstrates the importance of RNA splicing for cell type-specific regulation of gene expression. Besides transcriptional regulation and RNA interference, this biologic mechanism enables the cell to expand the limited amount of encoded genes toward the plethora of cell-specific proteins (42, 43) . RNA splice site selection has not previously been studied in podocytes but could add a novel level to understanding the complex biology of this highly specialized cell type. 165 isoform, shows an element with high similarity to the potential exonic splicing enhancers binding SLM-2 in other known genes: The sequences in the human transformer-2␤ (tra) exon 2, human tau exon 2, and murine CD44 exon v5 were described by Stoss et al. (22) . The human CD44 exon v5 and VEGF exon 7 were found by alignment. Identical nucleotides to the human VEGF exon 7 sequence are shown in bold. Figure 6 . Correlation of VEGF 165 isoform and SLM-2 in human biopsies. Expression of SLM-2 mRNA correlated positively with the expression of VEGF 165 in microdissected human glomeruli (r ϭ 0.63, P Ͻ 0.01). The expression levels of both genes were determined on isolated glomeruli of the 77 patients specified above; each patient's sample is represented by one dot.
The computational approach of DDD used in this study allowed for the first time the prediction of a cell type-specific gene expression by comparison of two organs with other cDNA libraries. This was possible because of the shared transcriptome of neuronal cells and podocytes. Although this successful proof of concept led to the identification of SLM-2, three limitations have to be discussed. First, SLM-2 has its most prominent expression in testis and therefore was even named testis-STAR (21) . The reason that our DDD results revealed this gene is the exclusion of testis in the list of organs included in the analysis. This was necessary because of the exhausting number of transcripts found in human testis, making a testis-included DDD screen almost impossible. Furthermore, for our approach, brain cDNA were especially important, and it was shown recently by Guo et al. (20) that the transcriptomes of brain and testis are the most similar ones. This made the exclusion of testis central for searching cDNA predominantly expressed in brain and kidney. The second limitation of our approach is the lack of suborganspecific cDNA libraries. The availability of glomerular cDNA libraries (instead of whole kidney) possibly would have increased the predictive impact of the analysis. More specific, the reason that no known podocyte-specific gene was found by the DDD experiment may be the low quantitative representation of podocytes in whole-kidney libraries. As third weakness of the DDD approach, one may call the low predictive value of 33% (one of three predicted genes confirmed). This predictive power is comparable with the ones of previous studies that used DDD, in which 20 to 30% of predicted templates could be confirmed (11, 44, 45) . It underlines the importance of confirmation experiments after computational analysis, but as with all novel techniques, the number of false-positive calls should decrease when DDD becomes a more frequently used tool for gene expression prediction.
This study stresses the potential that DDD has to predict cell type-specific gene expression. It allowed prediction of the podocyte-restricted expression of SLM-2 in the glomerulus. Along with the confirmation of this finding, SLM-2 was shown to be upregulated in proteinuric diseases and involved in splice site selection of VEGF. Studying the regulation of SLM-2 activity in vitro and in vivo may further elucidate alternative splicing as a central mechanism of podocyte biology.
